The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer

AbstractPurpose:. We describe the clinical and genomic landscape of the non–small cell lung cancer (NSCLC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC).Experimental Design:. A total of 1,846 patients with NSCLC whose tumors were sequenced from 2014 to 2018 at four institutions…

Read the full article here

Source: American Association for Cancer Research

Categories: Hem/Oncs, Latest Headlines

Tags: EGFR, kras

Tweets with this article

Stephen V Liu, MD

The @AACR GENIE BPC is an impressive resource with 1846 annotated NSCLC cases with NGS from 2014-18, described @CCR_AACR. In this dataset, 44% had an actionable alteration (20% #EGFR, 13% #KRAS G12C). Free access to explore! @NouraChoudhury @RielyMD https://t.co/2kGkYVpA6i

Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the ITMIG/ESTS Database

R0 resection and radiation therapy have been associated with improved OS in thymic carcinoma (TC) patients. Here we analyzed which subgroups of patients derive the…

Stephen V Liu April 26, 2024

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with…

Stephen V Liu April 24, 2024

A pragmatic guide for management of adverse events associated with lorlatinib

Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK…

Stephen V Liu April 22, 2024

2024 Texas Lung Cancer Conference Agenda

2024 Texas Lung Cancer Conference Agenda @TLCconference #TexasLung24

Stephen V Liu April 17, 2024

Completion Of Pembrolizumab In advanced non-small cell Lung cancer – real world Outcomes after Two years of therapy (COPILOT)

Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell…

Stephen V Liu April 17, 2024

Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab

Responses to first-line PD-1 inhibition vary among patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 TPS ≥50%. We previously reported improved clinical…

Stephen V Liu April 16, 2024

Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib.

For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical…

Stephen V Liu April 16, 2024

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2…

Stephen V Liu April 10, 2024

Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights

The landscape of treatment options for patients with advanced non–small cell lung cancer continues to evolve rapidly, with the recently updated non–small cell lung cancer…

Stephen V Liu April 10, 2024

Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias

Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death protein–ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibodies, have…

Stephen V Liu April 10, 2024

Related Articles